Abstract: The objective of the present invention is to provide a method for preparing cremation crystals, the method using phosphoric acid extracted from cremated remains as a catalyst in the heat treatment of ashes so that transparent cremation crystals can be prepared only with components of skeletal remains derived from a single individual, and using only skeletal remains of a single individual through the control of the classification ratio of raw bone powder and phosphorus-extracted bone powder, and the like, so that the amount of phosphorus in the crystals is controlled, thereby enabling cremation crystals transparency to be controlled, and thus aesthetic requirements of consumers are satisfied and use as various kinds of jewelry is also facilitated.

Abstract: An electrode assembly structure for a secondary battery includes an electrode assembly stack in which two or more electrode assemblies with electrode tabs extending in one direction are stacked and a current collecting member disposed on a first end portion of the electrode assembly stack and including a slit through which the electrode tab passes, wherein the electrode tab passes through the slit, and the electrode tab and the current collecting member are electrically connected.

Abstract: The present disclosure relates to an electrode assembly in which a plurality of first electrode plates including electrode tabs, a plurality of second electrode plates including electrode tabs, and a separator interposed between each of the first electrode plates and each of the second electrode plates are arranged in a stacked manner. In the electrode assembly, electrode tabs of the same polarity are bend-formed so that the electrode tabs are gathered at the center of the stacking direction of the electrode assembly and protrude outward, and sub-tabs may be bonded on the bend-formed electrode tabs. In addition, the present disclosure may include a manufacturing method of an electrode assembly in which a pair of sub-tabs is respectively bonded on opposite sides of a bundle of electrode tabs that are gathered at the center of the stacking direction of the electrode assembly and protrude outward as described above.

Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.

Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.

Abstract: The present invention relates to the effect of ciprofloxacin of inducing stem cells into chondroprogenitor cells or differentiating stem cells into chondrocytes. A pharmaceutical composition, chondroprogenitor cells, and chondrocytes according to the present invention may be used for preventing or treating cartilage-related diseases.

Abstract: Battery cutting devices are disclosed. In an implementation, a battery cutting device can cut a case of a secondary battery in a longitudinal direction, a thickness direction, and a width direction. The battery cutting device includes a jig unit fixing the secondary battery and a cutter unit cutting the secondary battery.

Abstract: Proposed is a method of forming cremation crystals, which is specifically a method of forming cremation crystals by using H3PO4 as a catalyst in a heat treatment process of ashes, thus preventing the ashes from being damaged by volatilization and enabling the crystals to be formed more efficiently. More specifically, proposed is a method of forming cremation crystals by mixing ashes with phosphoric acid obtained through the reduction of phosphorus in skeletal remains, which enables the cremation crystals composed purely of skeletal remains to be provided without additionally introducing other additives, thus satisfying the needs of families or guardians of the deceased desiring to keep cremation crystals composed purely of ashes, and enables both the color and transparency of ultimately formed cremation crystals to be achieved through a single formation process without limitation, thus satisfying the aesthetic needs of consumers and being easily applicable to all kinds of jewelry.

Abstract: The present invention relates to a heteroaryl derivative compound and a use thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against HER2 and EGFR, and thus can be effectively used as a therapeutic agent for HER2- and/or EGFR-associated diseases.

Abstract: Compositions include a curing agent of a fluorinated resorcinol or hydroquinone of Formula 1: R1 and R5 are independently H, halogen, optionally partially or fully halogenated C1-18 alkyl, optionally partially or fully halogenated C1-18 alkoxy, or X. R2-R4 are independently OH, H, halogen, optionally partially or fully halogenated C1-18 alkyl, optionally partially or fully halogenated C1-18 alkoxy, or X. At least one of R2, R3, and R4 is OH. Not more than 3 of R1-R5 are halogen. X is Formula 2 or Formula 3 as disclosed herein. Curable fluoroelastomer compositions, fluoroelastomer masterbatches, curing agent and curing accelerator mixtures, salts, and methods of curing a polyhydroxy-curable fluoroelastomer including a curing agent of a fluorinated resorcinol or hydroquinone of Formula 1 are also disclosed herein.

Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.

Abstract: The present invention relates to a heteroaryl derivative compound and a use thereof. Since the heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, the heteroaryl derivative can be usefully used as a therapeutic agent for EGFR-associated diseases.

Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.

Abstract: The present invention relates to a novel compound exhibiting enteropeptidase-inhibiting activity, a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing and treating metabolic diseases such as obesity, diabetes mellitus or hyperlipidemia, etc. comprising the compound or pharmaceutically acceptable salt, and a method for preventing or treating metabolic disease using the above novel compound. The compound of the present invention has excellent inhibitory activity against enteropeptidase, and thus is not absorbed into the body, but are excreted outside the body. However, since not only fat but also protein are discharged together, it has few side effects such as fat stools and acts only in the gastrointestinal tract, so it has few side effects such as depression, and is very useful as a therapeutic or prophylactic drug for various metabolic diseases such as obesity, diabetes mellitus, and hyperlipidemia.

Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.

Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.

Abstract: The present invention relates to a pyrrolo-pyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.

Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell limes, and thus can be usefully used in the treatment of lung cancer.

Abstract: The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.

Abstract: The present invention relates to a novel compound exhibiting enteropeptidase-inhibiting activity, a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing and treating metabolic diseases such as obesity, diabetes mellitus or hyperlipidemia, etc. comprising the compound or pharmaceutically acceptable salt, and a method for preventing or treating metabolic disease using the above novel compound. The compound of the present invention has excellent inhibitory activity against enteropeptidase, and thus is not absorbed into the body, but are excreted outside the body. However, since not only fat but also protein are discharged together, it has few side effects such as fat stools and acts only in the gastrointestinal tract, so it has few side effects such as depression, and is very useful as a therapeutic or prophylactic drug for various metabolic diseases such as obesity, diabetes mellitus, and hyperlipidemia.